gefitinib + erlotinib

gefitinib + erlotinib-Sichuan Provincial People's Hospital refers to a treatment regimen evaluated in the Phase III SINDAS trial (NCT02893332) led by Sichuan Provincial People's Hospital. This regimen involves the administration of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), specifically gefitinib or erlotinib, for the treatment of newly diagnosed EGFR-mutated oligometastatic stage IV non-small cell lung cancer (NSCLC). These small molecules function by competitively binding to the adenosine triphosphate (ATP) binding site of the EGFR tyrosine kinase domain, thereby inhibiting the autophosphorylation of the receptor and blocking downstream signaling pathways such as PI3K/Akt, MAPK/ERK, and JAK/STAT that promote tumor cell growth and survival. The SINDAS trial specifically investigated the efficacy of these TKIs when combined with consolidative stereotactic body radiation therapy (SBRT) compared to TKI monotherapy, demonstrating improved progression-free and overall survival in the combination arm.

Brand names

IressaTarceva

Other names

gefitiniberlotinibSINDAS regimen